Insmed Q3 revenue tops $524 million; Brinsupri, Arikayce guidance raised, Japan launch underwayNov 10M&AamikacinbrensocatibUpdated
United Therapeutics registers two SUMMIT trials of inhaled treprostinil SMI for PH-COPDNov 6Weekly roundup, 2 itemstreprostinilUnited Therapeutics
United Therapeutics posts TETON-2 Phase 3 results for inhaled Tyvaso in IPFOct 15Trial updatetreprostinilUnited Therapeutics
United Therapeutics: TYVASO DPI (NDA214324) SUPPL 7 approvedSep 23Regulatory decisiontreprostinilUnited TherapeuticsRecord notice
United Therapeutics discloses share count for $477.6 million ASR deal with CitiSep 8PartnershipUnited Therapeutics
Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal studyAug 12Quarterly updateLiquidia Corptreprostinil
United Therapeutics files two rare pulmonary disease NDAs, sets sights on approvals in 2027Aug 5Quarterly updateralinepagtreprostinil
FDA approves manufacturing supplement for Orenitram tablets from UNITED THERAPAug 4Regulatory decisiontreprostinilUnited Therapeutics
United Therapeutics posts results for terminated Phase 3 ralinepag CPET studyJul 6Trial updateralinepagUnited Therapeutics
United Therapeutics shareholders approve 2026 stock incentive plan at annual meetingJun 29PeopleUnited Therapeutics